華興資本參股的心通醫療正式在港上市:開盤大漲超80% 市值上500億港元
中國領先的高端心臟瓣膜介入醫療器械研發和製造企業心通醫療-B(02160.HK)今日正式登陸港交所。開盤股價高見22.2港元,截至發稿,報價19.14港元,漲幅56.89%。
心通醫療2月3日公佈的在港IPO招股結果顯示,公司全球發售約2.06億股,發售價定為12.20港元/股,為招股價上限,所得款項淨額估計約為23.56億港元。其香港公開發售獲得超過769倍認購。
心通醫療是微創醫療(00853.HK)旗下專注於介入心臟瓣膜業務的控股子公司。早在2017年8月,華傑天津、中金浦成及華泰瑞合就參與了心通醫療引戰項目,上述投資者以人民幣21億元估值認購了微創心通於該等交易完成後經擴大股本中將予新發行的約25%的股份權益。
格隆匯APP獲悉,華傑天津是華興資本旗下專注於醫療健康產業的私募股權投資基金,而華興資本(01911.HK)則是中國領先的服務新經濟的綜合類金融機構。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.